Clinical Trials
20
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2003
Active, not recruiting
5
25.0%
Completed
12
60.0%
Terminated
3
15.0%
No approval data available
- Pulmatrix will acquire Eos SENOLYTIX in a merger creating a first-in-class anti-aging biotechnology company focused on gerotherapeutic peptides targeting mitochondrial dysfunction. - The combined company will advance PTC-2105, a lead clinical candidate for sarcopenia and sarcopenic obesity that demonstrated improved body composition and physical function in preclinical studies. - A concurrent $19 million financing will support development of Eos's proprietary MitoXcel platform, which targets aging mechanisms through mitochondrial membrane potential modulation. - The merger addresses significant unmet medical needs in sarcopenia affecting tens of millions globally, with no currently approved therapies available.
- Pulmatrix and Cullgen have mutually agreed to waive the "No Solicitation" clause in their November 2024 merger agreement to explore alternative transactions while continuing to seek approval from China's Securities Regulatory Commission. - The merger has already received approval from Pulmatrix stockholders in June 2025 and SEC effectiveness for the Form S-4 filing in May 2025, but still awaits final regulatory clearance from Chinese authorities. - Pulmatrix maintains a robust pipeline of inhaled therapeutics using its proprietary iSPERSE technology, including PUR3100 for acute migraine treatment which is Phase 2-ready with FDA approval. - The company reported $4.8 million in cash and cash equivalents as of September 30, 2025, sufficient to fund operations through at least the fourth quarter of 2026.
- Pulmatrix plans to divest its clinical assets including PUR3100, a Phase 2-ready inhaled treatment for acute migraine, as part of its upcoming merger with Cullgen expected to close in June 2025. - The company's proprietary iSPERSE technology, which enables efficient pulmonary drug delivery with 146 granted patents, will also be divested as Pulmatrix transitions to focus on Cullgen's protein degradation platform. - First quarter 2025 financial results showed zero revenue (down from $5.9M in Q1 2024) with $7.7M cash on hand, which the company believes is sufficient to fund operations through the anticipated merger closing.
